Dr. Jeff Settleman, Ph.D., Chief Scientific Officer, Oncology Research and Development, Pfizer
Advertisement
Articles by Dr. Jeff Settleman, Ph.D., Chief Scientific Officer, Oncology Research and Development, Pfizer
Advertisement
Latest Updated Articles
- Bispecific antibodies in multiple myeloma: revolutionizing blood cancer immunotherapy
Published: June 21st 2024 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
3
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
4
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
5